Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maternal, infant care under global spotlight:

This article was originally published in Clinica

Executive Summary

Maternal and infant care are the focus of this year's global healthcare development campaign by the World Health Organization. It aims to reduce the estimated 30,000 deaths of children per day (around 11 million per year) and the high maternal mortality of Latin America - some 27 times higher than in the US. These have been attributed in large part to complications during pregnancy and childbirth that result primarily from under-resourced services or poor training.

You may also be interested in...



US Toning Down China CDMO Tension But New Restrictions Emerge

The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy. 

IRA Innovation Debate Showcased At House Hearing On Rare Disease Legislation

Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.

US FDA’s Califf: We Don’t Need Much Help From Congress On Rare Diseases

The FDA commissioner also does not want the agency setting goals for rare disease treatment development.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel